SIFI > International Markets
International Markets
In the last years SIFI has undergone a virtuous growth of its business, evolving into an industrial group of companies, consolidating domestic leadership and expanding into international markets.

Internationalization for SIFI Group means exporting a brand that is synonymous with specialization and tradition in ophthalmology, quality and innovation, ethics and professionalism, scientific education and proximity to physicians and patients, high medical and technological contents and commitment to social responsibility.

Today SIFI exports towards more than 20 countries with a direct presence in Italy, Spain, France, Romania, Mexico and Turkey.

Since June 2015, SIFI is backed by 21 Investimenti, a private equity firm founded by Alessandro Benetton, to support the company’s expansion strategy, which is based on establishing (or acquiring) direct commercial operations in major European markets and expanding its network of international distributors.

share & tag us with
#EyeCare #eyeinfo #health #innovation #business #eye #vision #leadership #pharma
#Development
“Vision is the art of seeing what is invisible to others.”
Jonathan Swift

 
 
Vision & History Established in 1935 by two local pharmacists in Sicily, SIFI started as a venture, specializing in the preparation of ophthalmic products. Since then, research, development,...
 
Code of Ethics SIFI SpA SIFI S.p.A. (Hereinafter also referred to as SIFI or the Company) has adopted ethical and behavioural principles that are consistent with the guidelines established...
 
Manufacturing In the last years SIFI has generated more than 60 patents and secured international alliances worldwide to export its growing portfolio overseas. Our product range spans from state-of-the-art...

On our Social Channels

From our News Center

SIFI, the main Italian ophthalmic pharmaceutical company, is actively involved in the fight against COVID-19, and is alongside physicians, nurses and health personnel, to help face together the...
 

 

23 October

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, and SIFI S.p.A. (“SIFI”), a prominent Italian...
Follow Us!